fda halts glp-1 New Pill Foundayo (Orforglipron) Gets Approval for Obesity GLP-1 Medications for Weight Loss:

Wall Street analysts anticipate the market for GLP-1 drugs alone could reach up to $100 BILLION within a decade

Impact of overweight on the risk of developing common chronic diseases during a 10-year period

Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review. Clinical Obesity, vol

Discontinuation: If symptoms are severe, persistent, or suggestive of hypersensitivity, discontinuing the medication may be necessary

And if you ever decide to switch medications, the guide on switching from tirzepatide to semaglutide or exploring alternatives to tirzepatide covers the transition process

However, it makes sense that obesity could affect disease course, as obesity is associated with chronic, systemic inflammation